-+ 0.00%
-+ 0.00%
-+ 0.00%
The Zhitong Finance App learned that Goldman Sachs released a research report saying that the third quarter results of CSPC Group (01093.HK) were in line with expectations. Despite the weak performance of the API business, the proprietary drug business remained steady, with a year-on-year increase of 10%, mainly due to the strong performance of central nervous system (CNS) related product lines. Among them, retail sales of the Group's core products “EnbiPu” and “Mingfule” continued to expand, driving related businesses to increase sharply by 32% year over year; however, the performance of the Group's anti-tumor product portfolio is still under pressure, and the release of materials will take time, and it has not yet become a new driving force for growth. Goldman Sachs maintained the “buy” rating of CSPC and raised the target price from HK$12.56 to HK$12.83.
Share
Listen to the news
The Zhitong Finance App learned that Goldman Sachs released a research report saying that the third quarter results of CSPC Group (01093.HK) were in line with expectations. Despite the weak performance of the API business, the proprietary drug business remained steady, with a year-on-year increase of 10%, mainly due to the strong performance of central nervous system (CNS) related product lines. Among them, retail sales of the Group's core products “EnbiPu” and “Mingfule” continued to expand, driving related businesses to increase sharply by 32% year over year; however, the performance of the Group's anti-tumor product portfolio is still under pressure, and the release of materials will take time, and it has not yet become a new driving force for growth. Goldman Sachs maintained the “buy” rating of CSPC and raised the target price from HK$12.56 to HK$12.83.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending